Nanomedicine, Volume IIA: Biocompatibility

© 2003 Robert A. Freitas Jr. All Rights Reserved.

Robert A. Freitas Jr., Nanomedicine, Volume IIA: Biocompatibility, Landes Bioscience, Georgetown, TX, 2003


References 2100-2199

2100. I.R. Pela, M.E. Ferreira, M.C. Melo, C.A. Silva, M.M. Coelho, C.F. Valenzuela, “Evidence that platelet-derived growth factor may be a novel endogenous pyrogen in the central nervous system,” Am. J. Physiol. Regul. Integr. Comp. Physiol. 278(May 2000):R1275-R1281.

2101. S.J.C. Warner, K.R. Auger, P. Libby, “Interleukin 1 induces interleukin 1. II. Recombinant human interleukin 1 induces interleukin 1 production by adult human vascular endothelial cells,” J. Immunol. 139(15 September 1987):1911-1917.

2102. T. Akahoshi, J.J. Oppenheim, K. Matsushima, “Interleukin 1 stimulates its own receptor expression on human fibroblasts through the endogenous production of prostaglandin(s),” J. Clin. Invest. 82(October 1988):1219-1224.

2103. K.P. Parker, W.R. Benjamin, K.L. Kaffka, P.L. Kilian, “Presence of IL-1 receptors on human and murine neutrophils: relevance to IL-1-mediated effects in inflammation,” J. Immunol. 142(15 January 1989):537-542.

2104. S. Takahashi, L. Kapas, J. Fang, J.M. Krueger, “Somnogenic relationships between tumor necrosis factor and interleukin-1,” Am. J. Physiol. 276(April 1999):R1132-R1140; J.M. Krueger, F. Obal Jr., M. Opp, L. Toth, L. Johannsen, A.B. Cady, “Somnogenic cytokines and models concerning their effects on sleep,” Yale J. Biol. Med. 63(March-April 1990):157-172.

2105. T. Ikejima, S. Okusawa, P. Ghezzi, J.W. van der Meer, C.A. Dinarello, “Interleukin-1 induces tumor necrosis factor (TNF) in human peripheral blood mononuclear cells in vitro and a circulating TNF-like activity in rabbits,” J. Infect. Dis. 162(July 1990):215-223.

2106. J.V. Desiderio, P.A. Kiener, P.F. Lin, G.A. Warr, “Protection of mice against Listeria monocytogenes infection by recombinant human tumor necrosis factor alpha,” Infect. Immun. 57(May 1989):1615-1617.

2107. R.C. Gaillard, D. Turnill, P. Sappino, A.F. Muller, “Tumor necrosis factor alpha inhibits the hormonal response of the pituitary gland to hypothalamic releasing factors,” Endocrinology 127(July 1990):101-106.

2108. E. Girardin, G.E. Gran, J.M. Dayer, P. Roux-Lombard, P.H. Lambert, “Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura,” N. Engl. J. Med. 319(18 August 1988):397-400.

2109. G.A. Filice, M.D. Weiler, R.A. Hughes, D.N. Gerding, “Nosocomial febrile illnesses in patients on an internal medicine service,” Arch. Intern. Med. 149(February 1989):319-324.

2110. R.G. Petersdorf, P.B. Beeson, “Fever of unexplained origin: report on 100 cases,” Medicine (Baltimore) 40(1961):1-.

2111. H.W. Murray, G.C. Ellis, D.S. Blumenthal, T.A. Sos, “Fever and pulmonary thromboembolism,” Am. J. Med. 67(August 1979):232-235.

2112. E.J. Young, V. Fainstein, D.M. Musher, “Drug-induced fever: cases seen in the evaluation of unexplained fever in a general hospital population,” Rev. Infect. Dis. 4(January-February 1982):69-77.

2113. J.D. Semel, “Fever associated with repeated intramuscular injections of analgesics,” Rev. Infect. Dis. 8(January-February 1986):68-72.

2114. M. Okuda, H. Yajima, S. Uchikoshi, T. Unno, “Basic study of nasal provocation test. Second report: assessment method on provocative reaction,” Arch. Otorhinolaryngol. 218(30 January 1978):203-207.

2115. J.M. Jausseran, N. Stella, M. Ferdani, E.C. Mialhe, “Endovascular treatment of abdominal aorta aneurysms using the Stentor device. Preliminary experience,” Minerva Cardioangiol. 44(November 1996):563-579.

2116. C. Minale, S. Nikol, G. Hollweg, C. Mittermayer, B.J. Messmer, “Clinical experience with expanded polytetrafluoroethylene Gore-Tex surgical membrane for pericardial closure: a study of 110 cases,” J. Card. Surg. 3(September 1988):193-201.

2117. H. Yao et al, “Clinical use of an expanded polytetrafluoroethylene sheets (GORE-TEX SHEETS) as a pericardial substitute after aorto coronary bypass grafting,” Kyobu Geka 46(March 1993):236-240. In Japanese.

2118. B.L. Dolmatch, Y.H. Dong, S.O. Trerotola, D.W. Hunter, L.H. Brennecke, R. LaBounty, “Tissue response to covered Wallstents,” J. Vasc. Interv. Radiol. 9(May-June 1998):471-478.

2119. S.F. Flaim, “Pharmacokinetics and side effects of perfluorocarbon-based blood substitutes,” Artif. Cells Blood Substit. Immobil. Biotechnol. 22(1994):1043-1054.

2120. R.E. Brubaker, “Pulmonary problems associated with the use of polytetrafluoroethylene,” J. Occup. Med. 19(October 1977):693-695.

2121. D.J. Shusterman, “Polymer fume fever and other fluorocarbon pyrolysis-related syndromes,” Occup. Med. 8(July-September 1993):519-531.

2122. K. Sunami, I. Yamadori, T. Kishimoto, S. Ozaki, Y. Kawabata, “Unilateral mixed-dust pneumoconiosis with aluminum deposition associated with interstitial pneumonia,” Nihon Kyobu Shikkan Gakkai Zasshi 35(February 1997):189-195.

2123. D.M. Chen, “Synthesizing and biological quality of hydroxyapatite (HAP) ceramics,” Chung Hua Kou Chiang Hsueh Tsa Chih 26(September 1991):294-296.

2124. P.V. Offermann, C.J. Finley, “Metal fume fever,” Ann. Emerg. Med. 21(July 1992):872-875.

2125. J.M. Fine, T. Gordon, L.C. Chen, P. Kinney, G. Falcone, W.S. Beckett, “Metal fume fever: characterization of clinical and plasma IL-6 responses in controlled human exposures to zinc oxide fume at and below the threshold limit value,” J. Occup. Environ. Med. 39(August 1997):722-726.

2126. W.G. Kuschner, A. D’Alessandro, J. Hambleton, P.D. Blanc, “Tumor necrosis factor-alpha and interleukin-8 release from U937 human mononuclear cells exposed to zinc oxide in vitro. Mechanistic implications for metal fume fever,” J. Occup. Environ. Med. 40(May 1998):454-459.

2127. S. Chan, B. Gerson, S. Subramaniam, “The role of coppper, molybdenum, selenium, and zinc in nutrition and health,” Clin. Lab. Med. 18(December 1998):673-685.

2128. S.E. Malawista, G.W. Duff, E. Atkins, H.S. Cheung, D.J. McCarty, “Crystal-induced endogenous pyrogen production. A further look at gouty inflammation,” Arthritis Rheum. 28(September 1985):1039-1046; F.S. di Giovine, S.E. Malawista, G. Nuki, G.W. Duff, “Interleukin 1 (IL 1) as a mediator of crystal arthritis. Stimulation of T cell and synovial fibroblast mitogenesis by urate crystal-induced IL 1,” J. Immunol. 138(15 May 1987):3213-3218.

2129. G.W. Duff, E. Atkins, S.E. Malawista, “The fever of gout: urate crystals activate endogenous pyrogen production from human and rabbit mononuclear phagocytes,” Trans. Assoc. Am. Physicians 96(1983):234-245.

2130. P.A. Guerne, R. Terkeltaub, B. Zuraw, M. Lotz, “Inflammatory microcrystals stimulate interleukin-6 production and secretion by human monocytes and synoviocytes,” Arthritis Rheum. 32(November 1989):1443-1452.

2131. R.F. Kampschmidt, M.L. Worthington 3rd, M.I. Mesecher, “Release of interleukin-1 (IL-1) and IL-1-like factors from rabbit macrophages with silica,” J. Leukoc. Biol. 39(February 1986):123-132.

2132. C. Dumontet, F. Biron, D. Vitrey, J.C. Guerin, M. Vincent, O. Jarry, D. Meram, D. Peyramond, “Acute silicosis due to inhalation of a domestic product,” Am. Rev.Respir. Dis. 143(April 1991):880-882.

2133. R.N. Miranda, P.N. McMillan, V.E. Pricolo, S.D. Finkelstein, “Peritoneal silicosis,” Arch. Pathol. Lab. Med. 120(March 1996):300-302.

2134. A. Weinberger, A. Kesler, J. Pinkhas, “Fever in various rheumatic diseases,” Clin. Rheumatol. 4(September 1985):258-266.

2135. G. Ho Jr., M. DeNuccio, “Gout and pseudogout in hospitalized patients,” Arch. Intern. Med. 153(27 December 1993):2787-2790.

2136. F.S. di Giovine, S.E. Malawista, E. Thornton, G.W. Duff, “Urate crystals stimulate production of tumor necrosis factor alpha from human blood monocytes and synovial cells. Cytokine mRNA and protein kinetics, and cellular distribution,” J. Clin. Invest. 87(April 1991):1375-1381.

2137. P. Le Goff, Y. Pennec, P. Youinou, “Articular chondrocalcinosis revealed by acute cervical symptoms simulating meningitis,” Sem. Hop. 56(15 October 1980):1515-1518. In French.

2138. D.J. McCarty, “Arthropathies associated with calcium-containing crystals,” Hosp. Pract. (Off. Ed.) 21(15 October 1986):109-115, 118-120.

2139. R.G. Berger, P.M. Levitin, “Febrile presentation of calcium pyrophosphate dihydrate deposition disease,” J. Rheumatol. 15(April 1988):642-643.

2140. J.J. de Haan, C.B. Andreasen, “Calcium crystal-associated arthropathy (pseudogout) in a dog,” J. Am. Vet. Med. Assoc. 200(1 April 1992):943-946.

2141. M.E. Mavrikakis, L.G. Antoniades, S.A. Kontoyannis, D.S. Moulopoulou, C.P. Papamichael, C.C. Kostopoulos, P.H. Athanassiades, “CPPD crystal deposition disease as a cause of unrecognized pyrexia,” Clin. Exp. Rheumatol. 12(July-August 1994):419-422.

2142. S. Imai, S. Hukuda, “Cervical radiculomyelopathy due to deposition of calcium pyrophosphate dihydrate crystals in the ligamentum flavum: historical and histological evaluation of attendant inflammation,” J. Spinal Disord. 7(December 1994):513-517.

2143. D. Aeberli, Z. Stanga, N.J. Gerber, “Fever of unknown origin as a sign of calcium pyrophosphate deposition disease,” Schweiz. Med. Wochenschr. 130(8 April 2000):505-509. In German.

2144. F. Mateos Anton, “Kidney lithiasis: to treat the fever or to determine and treat its cause?” Arch. Esp. Urol. 43(April 1990):217-220. In Spanish.

2145. G.B. Fogazzi, “Crystalluria: a neglected aspect of urinary sediment analysis,” Nephrol. Dial. Transplant. 11(February 1996):379-387.

2146. S.K. Swanson, R.L. Heilman, W.G. Eversman, “Urinary tract stones in pregnancy,” Surg. Clin. North Am. 75(February 1995):123-142.

2147. C. Gonzalez Enguita, I. Jimenez Jimenez, J. Perez Perez, R. Montero Rubio, M.J. Cancho Gil, R. Vela Navarrete, “Renal colic and lithiasis in HIV(+)-patients treated with protease inhibitors,” Actas Urol. Esp. 24(March 2000):212-218. In Spanish.

2148. J.D. Haines Jr., “Coughing up a stone. What to do about broncholithiasis,” Postgrad. Med. 83(15 February 1988):83-84, 91.

2149. E. Avrahami, M. Englender, E. Chen, D. Shabtay, R. Katz, M. Harell, “CT of submandibular gland sialolithiasis,” Neuroradiology 38(April 1996):287-290.

2150. J.S. Reedy, J.E. Kuhlman, M. Voytovich, “Microvascular pulmonary emboli secondary to precipitated crystals in a patient receiving total parenteral nutrition: a case report and description of the high-resolution CT findings,” Chest 115(March 1999):892-895.

2151. J.K. Johnston, T.J. Divers, V.B. Reef, H. Acland, “Cholelithiasis in horses: ten cases (1982-1986),” J. Am. Vet. Med. Assoc. 194(1 February 1989):405-409.

2152. J. Kirpensteijn, R.B. Fingland, T. Ulrich, D.A. Sikkema, S.W. Allen, “Cholelithiasis in dogs: 29 cases (1980-1990),” J. Am. Vet. Med. Assoc. 202(1 April 1993):1137-1142.

2153. U. Scheurer, “Clinical manifestations of cholelithiasis and its complications,” Schweiz. Rundsch. Med. Prax. 84(16 May 1995):590-595. In German.

2154. M.J. Fine, W. Kapoor, V. Falanga, “Cholesterol crystal embolization: a review of 221 cases in the English literature,” Angiology 38(October 1987):769-784; M. Ghannem, J. Philippe, A. Ressam, D. Rechtman, M. Zaghdoudi, P. Taveneau, A. Calibre, “Systemic cholesterol embolism,” Ann. Cardiol. Angeiol. (Paris) 44(October 1995):422-426. In French.

2155. R.P. Donnelly, M.J. Fenton, D.S. Finbloom, T.L. Gerrard, “Differential regulation of IL-1 production in human monocytes by IFN-gamma and IL-4,” J. Immunol. 145(15 July1990):569-575.

2156. W.P. Arend, “Interleukin 1 receptor antagonist: a new member of the interleukin 1 family,” J. Clin. Invest. 88(November 1991):1445-1451.

2157. P. Conti, M.R. Panara, S. Fridas, R.C. Barbacane, A. Grilli, F.C. Placido, M. Reale, S. Fiore, “Inhibition of granuloma formation induced by potassium permanganate in the mouse by a specific human recombinant receptor antagonist for interleukin-1 (hrIL-1ra),” Cell Immunol. 147(1 April 1993):446-457.

2158. D.J. Nikolic-Paterson, H.Y. Lan, R.C. Atkins, “Interleukin-1 receptor antagonism,” Semin. Nephrol. 16(November 1996):583-590.

2159. C.A. Dinarello, “Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist,” Int. Rev. Immunol. 16(1998):457-499; “Induction of interleukin-1 and interleukin-1 receptor antagonist,” Semin. Oncol. 24(June 1997):S9-81 - S9-93 (3 Suppl 9); “Interleukin-1 and interleukin-1 antagonism,” Blood 77(15 April 1991):1627-1652.

2160. B. Bresnihan, G. Cunnane, “Interleukin-1 receptor antagonist,” Rheum. Dis. Clin. North Am. 24(August 1998):615-628.

2161. R. Brattsand, M. Linden, “Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies,” Aliment. Pharmacol. Ther. 10 Suppl 2(1996):81-90, 91-92 (discussion).

2162. S.B. Abramson, “Treatment of gout and crystal arthropathies and uses and mechanisms of action of nonsteroidal anti-inflammatory drugs,” Curr. Opin. Rheumatol. 4(June 1992):295-300.

2163. J. Hulkkonen, P. Laippala, M. Hurne, “A rare allele combination of the interleukin-1 gene complex is associated with high interleukin-1b plasma levels in healthy individuals,” Eur. Cytokine Netw. 11(April 2000):251-255.

2164. Stephen R. Wilson, Austin N. Kirschner, Bernard F. Erlanger, Bradford C. Braden, presentation at NanoSpace 2000, reported by R. Dagani, “NASA Goes Nano,” Chem. Eng. News 78(28 February 2000):39-42. See also:

2165. E.D. Carosella, J. Dausset, N. Rouas-Freiss, “Immunotolerant functions of HLA-G,” Cell Mol. Life Sci. 55(March 1999):327-333.

2166. P. Paul, N. Rouas-Freiss, I. Khalil-Daher, P. Moreau, B. Riteau, F.A. Le Gal, M.F. Avril, J. Dausset, J.G. Guillet, E.D. Carosella, “HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance,” Proc. Natl. Acad. Sci. (USA) 95(14 April 1998):4510-4515;

2167. J.Y. Djeu, “Natural killer cells. Role in resistance to cancer and infection,” J. Fla. Med. Assoc. 78(November 1991):763-765.

2168. L.L. Lanier, “The origin and functions of natural killer cells,” Clin. Immunol. 95(April 2000):S14-S18.

2169. W.E. Seaman, “Natural killer cells and natural killer T cells,” Arthritis Rheum. 43(June 2000):1204-1217.

2170. Sandra R. Whaley, Doug S. English, Evelyn L. Hu, Paul F. Barbara, Angela M. Belcher, “Selection of peptides with semiconductor binding specificity for directed nanocrystal assembly,” Nature 405(8 June 2000):665-668. Comment at: C.A. Mirkin, T.A. Taton, “Semiconductors meet biology,” Nature 405(8 June 2000):626-627;; Angela M. Belcher homepage,; Belcher research group website:

2171. D.H. Raulet, “Development and tolerance of natural killer cells,” Curr. Opin. Immunol. 11(April 1999):129-134; D.H. Raulet, W. Held, I. Correa, J.R. Dorfman, M.F. Wu, L. Corral, “Specificity, tolerance and developmental regulation of natural killer cells defined by expression of class I-specific Ly49 receptors,” Immunol. Rev. 155(February 1997):41-52.

2172. Health Effects Institute, “Report #95 – Association of Particulate Matter with Daily Mortality and Morbidity in Urban Populations,” June 2000; See also: Jocelyn Kaiser, “Evidence mounts that tiny particles can kill,” Science 289(7 July 2000):22-23.

2173. G. Angus McQuibban, Jiang-Hong Gong, Eric M. Tam, Christopher A.G. McCulloch, Ian Clark-Lewis, Christopher M. Overall, “Inflammation Dampened by Gelatinase A Cleavage of Monocyte Chemoattractant Protein-3,” Science 289(18 August 2000):1202-1206.

2174. D.F. Lewis, C. Ioannides, D.V. Parke, “Prediction of chemical carcinogenicity from molecular and electronic structures: a comparison of MINDO/3 and CNDO/2 molecular orbital methods,” Toxicol. Lett. 45(January 1989):1-13.

2175. K. Enslein, V.K. Gombar, B.W. Blake, “International Commission for Protection Against Environmental Mutagens and Carcinogens. Use of SAR in computer-assisted prediction of carcinogenicity and mutagenicity of chemicals by the TOPKAT program,” Mutat. Res. 305(1 February 1994):47-61; “Assessment of developmental toxicity potential of chemicals by quantitative structure-toxicity relationship models,” Chemosphere 31(July 1995):2499-2510.

2176. A.M. Richard, “Structure-based methods for predicting mutagenicity and carcinogenicity: are we there yet?” Mutat. Res. 400(25 May 1998):493-507.

2177. C.J. Moudgal, J.C. Lipscomb, R.M. Bruce, “Potential health effects of drinking water disinfection by-products using quantitative structure toxicity relationship,” Toxicology 147(8 June 2000):109-131.

2178. E. Zeiger, “Mutagenicity of chemicals added to food,” Mutat. Res. 290(November 1993):53-61.

2179. A. Hartwig, “Current aspects in metal genotoxicity,” Biometals 8(January 1995):3-11.

2180. R.E. Powers, G.P. Lawton, I.M. Modlin, “Genotoxicity, carcinogenicity and acid-suppressing medications,” Pharmacol. Ther. 65(March 1995):303-317.

2181. M.R. Juchau, “Chemical teratogenesis in humans: biochemical and molecular mechanisms,” Prog. Drug Res. 49(1997):25-92.

2182. J.B. Bishop, K.L. Witt, R.A. Sloane, “Genetic toxicities of human teratogens,” Mutat. Res. 396(12 December 1997):9-43.

2183. R.H. Finnell, “Teratology: general considerations and principles,” J. Allergy Clin. Immunol. 103(February 1999):S337-S342.

2184. J.R.M. Innes et al, “Bioassay of pesticides and industrial chemicals for tumorigenicity in mice: a preliminary note,” J. Natl. Cancer Inst. 42(June 1969):1101-1114.

2185. B.N. Ames, L.S. Gold, “Too many rodent carcinogens: mitogenesis increases mutagenesis,” Science 249(31 August 1990):970-971; “Chemical carcinogenesis: too many rodent carcinogens,” Proc. Natl. Acad. Sci. (USA) 87(October 1990):7772-7776; L.S. Gold, T.H. Slone, B.N. Ames, “What do animal cancer tests tell us about human cancer risk? Overview of analyses of the carcinogenic potency database,” Drug Metab. Rev. 30(May 1998):359-404.

2186. S. Preston-Martin, M.C. Pike, R.K. Ross, P.A. Jones, B.E. Henderson, “Increased cell division as a cause of human cancer,” Cancer Res. 50(1 December 1990):7415-7421.

2187. P.R. Bouchard, J. Black, B.A. Albrecht, R.E. Kaderly, J.O. Galante, B.U. Pauli, “Carcinogenicity of CoCrMo (F-75) implants in the rat,” J. Biomed. Mater. Res. 32(September 1996):37-44.

2188. S. Vieira de Oliveira, J.L. Viana de Camargo, P.R. Cardoso, C.R. Padovani, S. Fukushima, “Effects of uracil calculi on cell growth and apoptosis in the BBN-initiated Wistar rat urinary bladder mucosa,” Teratog. Carcinog. Mutagen. 19(1999):293-303.

2189. N.G. Heselson, S.K. Price, E.E.D. Mills, S.S.M. Conway, R.K. Marks, “Two malignant fibrous histiocytomas in bone infarcts. Case report,” J. Bone Joint Surg. 65(October 1983):1166-1171.

2190. D. Theegarten, M. Meisel, “Malignant fibrous histiocytoma of the thoracic wall in the area of a tuberculous pleural callocity,” Pneumologie 47(July 1993):458-460. In German.

2191. M.D. Alconchel, C. Olivares, R. Alvarez, “Squamous cell carcinoma, malignant melanoma and malignant fibrous histiocytoma arising in burn scars,” Br. J. Dermatol. 137(November 1997):793-798.

2192. S. Kenan, I.F. Abdelwahab, G. Hermann, M.J. Klein, “Malignant fibrous histiocytoma associated with a bone infarct in a patient with hereditary bone dysplasia,” Skeletal Radiol. 27(August 1998):463-467.

2193. K.G. Brand, in F.F. Becker, ed., Cancer: A Comprehensive Treatise, Volume 1, Plenum Press, New York, 1975, pp. 485-.

2194. D.J. Ferguson, “Cellular attachment to implanted foreign bodies in relation to tumorigenesis,” Cancer Res. 37(December 1977):4367-4371.

2195. E.J. Andrews, P.W. Todd, N.E. Kukulinsky, “Surface charge in foreign body carcinogenesis,” J. Biomed. Mater. Res. 13(March 1979):173-187.

2196. C.W. Boone, N. Takeichi, S. del A. Eaton, M. Paranjpe, “Spontaneous neoplastic transformation in vitro: a form of foreign body (smooth surface) tumorigenesis,” Science 204(13 April 1979):177-179.

2197. T.G. Moizhess, J.M. Vasiliev, “Early and late stages of foreign-body carcinogenesis can be induced by implants of different shapes,” Int. J. Cancer 44(15 September 1989):449-453; “Tumorigenicity of sarcoma cells is enhanced by the local environment of implanted foreign body,” Int. J. Cancer 30(15 October 1982):525-529.

2198. G.E. Moore, “Foreign body carcinogenesis,” Cancer 67(1 June 1991):2731-2732.

2199. M. Mhic Iomhair, S.M. Lavelle, “Effect of 3 growth control substances on foreign body sarcomagenesis: IFN, IUdR, MGBG,” Ir. J. Med. Sci. 168(January-March 1999):42-44.


Last updated on 16 April 2004